Advertisement
News
Subscribe to Drug Discovery & Development News

The Lead

Merck Buys Swiss Biotech Firm With Promising Cancer Drug

December 19, 2014 | Comments

Merck is buying a biotech company based in Switzerland that is making a promising cancer drug. Read more...                          

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AstraZeneca Cancer Drug, Companion Test Approved

December 19, 2014 3:08 pm | by Linda A. Johnson - AP Business Writer | Comments

U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from AstraZeneca. Read more...                 

TOPICS:

FDA Approves Myriad's PARP Inhibitor for Ovarian Cancer

December 19, 2014 2:08 pm | Comments

Myriad Genetics, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca’s drug Lynparza (olaparib). Read more...

TOPICS:

After Lung Transplant, Antiviral Drug Resistance More Likely in Cystic Fibrosis

December 19, 2014 1:50 pm | Comments

A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation. Read more...                                                     

TOPICS:
Advertisement

Putting the Breaks on Cancer

December 19, 2014 1:38 pm | Comments

A study led by the University of Dundee, in collaboration with the University of Bath, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how it combats the effects of mutations which drive cancer development. Read more...

TOPICS:

Market for Testing On Tissues, Cells Reaches $7.5B

December 19, 2014 1:06 pm | Comments

Driven by new technologies and the need to discover biomarkers, the tissue and cell-based diagnostic market grew to an estimated 7.4 billion in revenues in 2013 for in vitro diagnostic (IVD) and other reagents used by clinical laboratories. Read more...

TOPICS:

UN Chief Visits Ebola-Ravaged West African Nations

December 19, 2014 10:18 am | by Jonathan Paye-Layleh - Associated Press | Comments

United Nations Secretary-General Ban Ki-moon praised Liberia on its efforts to combat Ebola on Friday. Read more...                        

TOPICS:

Company Pioneers High Performance Anti-Pruritus Nanopatch

December 19, 2014 10:06 am | Comments

A Hong Kong company successfully developed and registered the world's first ever high-performance anti-pruritus nanopatch. Read more...                     

TOPICS:

New Disease Mechanism Discovered in Lymphoma

December 18, 2014 11:34 am | by Technical University - Munich | Comments

Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. Read more...                          

TOPICS:
Advertisement

Warehouse Holding Ebola Supplies in Guinea Catches Fire

December 18, 2014 11:28 am | by Boubacar Diallo - Associated Press | Comments

A Guinean official says a fire at a warehouse at the Conakry airport has destroyed crucial medicine to help fight Ebola. Dr. Moussa Konate, head of logistics for Guinea's Ebola response, said that the fire on Thursday morning engulfed a building holding medicine, like anti-malarials and antibiotics. Read more...

TOPICS:

Hypertension Medication that Targets Stress May Help Smokers Quit

December 18, 2014 11:23 am | by Daniel Jones, Yale University | Comments

Smokers trying to quit often light up a cigarette to deal with stress. Now an interdisciplinary team of Yale researchers has shown that guanfacine, a medication approved for treating hypertension that reduces stress and enhances cognition, shows promise as a smoking cessation aid. Read more...

TOPICS:

Microcapsule Eliminates Toxic Punch of Experimental Anti-Cancer Drug

December 18, 2014 11:15 am | by Johns Hopkins | Comments

Johns Hopkins researchers have developed a sugar-based molecular microcapsule that eliminates the toxicity of an anticancer agent developed a decade ago at Johns Hopkins, called 3-bromopyruvate, or 3BrPA, in studies of mice with implants of human pancreatic cancer tissue. Read more..

TOPICS:

Supplement Maker Admits Lying About Ingredients

December 18, 2014 11:03 am | Comments

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.. Read more...                                              

TOPICS:

Inovio Initiates DNA Immunotherapy Trial for Cancers

December 18, 2014 10:48 am | Comments

Inovio Pharmaceuticals, Inc. announced it has initiated a phase 1 trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's 1L-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments. Read more...

TOPICS:

Enamine, Sanofi Extend Early Drug Discovery Collaboration

December 18, 2014 9:06 am | Comments

Enamine and Sanofi extend partnership for early drug discovery. Read more...                               

TOPICS:

GSK Shingles Vaccine Hits Goal in Major Study

December 18, 2014 9:02 am | Comments

GSK announced that a pivotal phase 3 study to assess the efficacy of HZ/su, an investigational vaccine for the prevention of shingles, has met its primary endpoint. Read more...                                 

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading